Subject: Ozempic/Wegovy shortage “over” + what it means for compounded semaglutide
Preview text: If you’ve been using compounded semaglutide (or thinking about it), the rules of the road are shifting—plus a clear-eyed look at what time-restricted eating can (and can’t) do.
1) Today’s News Headlines
The FDA’s move to formally end the Ozempic/Wegovy shortage is changing the access landscape—and may tighten the window for compounded semaglutide in many cases. (washingtonpost.com)
At the same time, Medicaid coverage for GLP-1s for obesity remains limited and is shrinking in several states due to cost pressures—meaning “available” doesn’t always equal “affordable.” (kff.org)
2) Today’s Top Stories
Wegovy/Ozempic shortage declared over—compounded semaglutide faces a crackdown timeline
The FDA has said the Ozempic/Wegovy shortage is over, a pivotal shift after years of constrained supply. That change could restrict routine compounding of semaglutide “copies” (with limited exceptions under compounding law), though patients may still see intermittent/local disruptions as the market adjusts. (washingtonpost.com)
Why it matters: If you’ve relied on compounded semaglutide because of cost or access, you may need a proactive transition plan with your prescriber now.
Source: Washington Post (washingtonpost.com)
Medicaid GLP-1 coverage for obesity: only 13 states as of Jan 2026—and some states recently pulled back
A new KFF review reports that just 13 state Medicaid programs cover GLP-1s for obesity treatment under fee-for-service as of January 2026, and several states have recently eliminated coverage, largely due to budget impact. Utilization controls (like prior authorization) are common even where coverage exists. (kff.org)
Why it matters: Coverage is becoming a moving target—if you’re on Medicaid, your state’s policy can change faster than your clinical needs.
Source: KFF (Kaiser Family Foundation) (kff.org)
FDA: GLP-1 weight-loss drugs shouldn’t carry suicide warnings
The FDA has advised companies to remove suicide-related warnings from certain obesity GLP-1 drug labels after reviewing data and not finding evidence of increased risk of suicidal thoughts/behaviors. (apnews.com)
Why it matters: Accurate labeling matters—this is a reminder to focus on known, common side effects and individualized monitoring rather than fear-driven headlines.
Source: Associated Press (apnews.com)
Celebrity lens: Oprah on GLP-1s and “wasted shame”—a helpful reframing
Oprah Winfrey shared regret about not having access to GLP-1s earlier and described the emotional relief of reduced “food noise,” reinforcing a disease-model understanding of obesity rather than a willpower narrative. (businessinsider.com)
Why it matters: Shame is not a strategy—reducing self-blame can improve follow-through on any plan (medication, lifestyle, or both).
Source: Business Insider (businessinsider.com)
3) Deep Dive (Tuesday): Science Simplified
Time-Restricted Eating (TRE): what the research says—and what people get wrong
The study (in plain language):
A randomized controlled trial in adults with metabolic syndrome found that a personalized 8–10 hour eating window led to a modest improvement in HbA1c (~0.10%) compared with standard-of-care, with no major adverse events reported. (pubmed.ncbi.nlm.nih.gov)
What TRE can do (realistic benefits)
- Can reduce “grazing” and mindless evening intake by creating a simple boundary: “kitchen closed.”
- May modestly improve glycemic regulation in some people—especially if it reduces late-night eating and overall calories without feeling like constant restriction. (pubmed.ncbi.nlm.nih.gov)
- Can be easier than tracking, for some personalities: fewer decisions, less negotiating.
What TRE can’t magically do (myth-busting, kindly)
- Myth: “TRE works even if you eat whatever you want.”
Reality: Many TRE benefits likely come from what changes alongside the window—total calories, ultra-processed snack reduction, alcohol reduction, and better sleep timing. TRE isn’t a free pass; it’s a structure. (pubmed.ncbi.nlm.nih.gov) - Myth: “Fasting always beats a balanced diet.”
Reality: In a 2025 randomized trial comparing several calorie-restricted approaches, some patterns (e.g., ketogenic diet, modified alternate-day fasting, and late TRE) produced more weight loss than a calorie-restricted Mediterranean-style approach over 3 months—but the differences were measured in kilograms, not miracles, and adherence is the long game. (bmcmedicine.biomedcentral.com)
Practical takeaways (pick one to try this week)
- Start with a 12-hour window (e.g., 8am–8pm) for 7 days—then narrow only if it feels stable.
- Protect protein at the first meal (aim ~25–35g) to reduce rebound hunger later.
- If nights are your danger zone, make TRE an evening strategy, not a morning punishment: keep breakfast normal, and simply set a consistent “last call.”
Safety note (important): If you’re on glucose-lowering meds (including insulin) or have a history of disordered eating, TRE should be discussed with your clinician to avoid hypoglycemia or triggering restrictive cycles. (pubmed.ncbi.nlm.nih.gov)
4) Quick Hits
- If you’re using compounded semaglutide, ask your clinician: “What’s our 60–90 day plan if my compound stops?” (dose equivalence, prior auth timing, pharmacy access). (washingtonpost.com)
- Medicaid note: even in states that cover obesity GLP-1s, prior authorization is common—build time for paperwork and appeals. (kff.org)
- Labeling headlines can be noisy: the FDA’s position on suicide warnings is a reminder to focus on known common side effects (GI symptoms, constipation, etc.) and individualized monitoring. (apnews.com)
- A helpful mindset reframe from Oprah’s comments: treat obesity management like any chronic condition—tools can be ongoing, and that’s not failure. (businessinsider.com)
- If TRE interests you, consider a “weekend flex” (slightly wider window Sat/Sun) to make it sustainable rather than perfect. (pubmed.ncbi.nlm.nih.gov)
- If you’re trying to lose weight while in perimenopause/menopause, you’re not imagining it—some people need a new toolset (training, protein, sleep, sometimes medication). (See celebrity discussion as cultural signal, not a protocol.) (instyle.com)
5) By The Numbers
13 — the number of state Medicaid programs covering GLP-1s for obesity treatment under fee-for-service as of January 2026 (per KFF). (kff.org)
What it means: Access is uneven—and can change quickly with budgets.
Why you should care: If coverage is critical for your plan, you may need to plan for contingencies (appeals, alternative meds, or intensified lifestyle support during gaps). (kff.org)
6) Ask The Community
If your access to GLP-1 medication changed tomorrow (cost, coverage, supply), what’s the one lifestyle habit you’d double down on to protect your progress?
7) Tomorrow’s Preview
Community Voices: a real-world strategy breakdown—how someone built consistency (and kept it) when motivation wasn’t showing up.